Disruptive technologies for formulation, stabilisation and delivery of therapeutic proteins



January 21, 2015

In this video an aqueous protein/parenteral excipient formulation is flow-precipitated at room temperature and pressure to form a suspension of dehydrated protein microparticles. Even at this lab-scale, protein is processed at 5g per min and can then be secondary dried by vacuum or SCFE depending on the application. A GMP compliant process has been built and a manufacturing plant is being developed. XstalBio's flow-precipitation technology provides a versatile platform for processing therapeutic proteins and vaccines into extremely stable dry powders. Applications include inhalable biologic powders, concentration of therapeutic proteins, such as mAbs, to >150 mg/ml, intermediate solid-state storage of sensitive proteins, such as ADC, sustained release formulations of proteins and cold-chain free oral vaccines.

These patented technologies are available for licensing from XstalBio. Please visit www.xstalbio.com or contact Dr. Marie Claire Parker by calling +44 141 330 3801.

BiopharmaDrug Discovery

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.